PFE Jan 2024 57.500 put
| Previous Close | 14.05 |
| Open | 14.05 |
| Bid | 17.10 |
| Ask | 17.50 |
| Strike | 57.50 |
| Expire Date | 2024-01-19 |
| Day's Range | 14.05 - 14.05 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 16 |
- Motley Fool
Could This Move by Johnson & Johnson Equal Billions for Moderna?
What does big pharma Johnson & Johnson (NYSE: JNJ) have in common with biotech Moderna (NASDAQ: MRNA)? Last week, however, Johnson & Johnson said it would discontinue its adult RSV program. Could the J&J news eventually translate into billions of dollars for Moderna?
- Motley Fool
3 Surprisingly Underrated Stocks to Buy in April
Here's why they chose Axsome Therapeutics (NASDAQ: AXSM), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE) as opportunities that especially stand out. Prosper Junior Bakiny (Axsome Therapeutics): Last year, Axsome Therapeutics' share price doubled, partly due to the FDA approving its depression medicine Auvelity for use. The company's stock is down by 19% since the start of the year.
- Motley Fool
If You Invested $25,000 in Pfizer in 2020, This Is How Much You Would Have Today
Investing in top COVID-19 vaccine maker Pfizer (NYSE: PFE) seems like it should have made you rich if you bought the stock in March 2020. On March 2, 2020, Pfizer's stock was selling for $33 a share. It would be nearly a year before Pfizer had an approved COVID-19 vaccine, which was produced in partnership with BioNTech.
